Sun Pharma Shares Rise After FDA Approval For Cancer Drug

By Admin
The firm, which is headquartered in Mumbai released a statement saying that its subsidiary has received the green light for US Food and Drug Administr...

 

The firm, which is headquartered in Mumbai released a statement saying that its subsidiary has received the green light for US Food and Drug Administration for its Doxorubicin HCI Liposome Injection.  

“This generic Doxorubicin HCl Liposome injection USP, 2 mg/ml is therapeutically equivalent to Doxil Liposome Injection, 2 mg/ml of Janssen Research and Development, LLC,” the company said.

Doxorubicin HCl liposome injection is used to treat patients with ovarian cancer, which has progressed or recurred after platinum-based chemotherapy.

Reacting to the development, shares of Sun Pharma were trading at Rs 745.70 on the BSE in afternoon trade, up 3.84 percent from their previous close. 

Share

Featured Articles

Why clinical AI is the future of healthcare

Harish Battu from General Catalyst explores the use of AI in healthcare, the challenges of its adoption & what it means for healthcare technology

AI can help healthcare workers deliver compassionate care

Dr. Lance Owens, Chief Medical Information Officer at the University of Michigan Health-West, explains how AI technology can support healthcare workers

Digital healthcare platform Balanced supports healthy ageing

10,000 people turn 65 in the USA each day. Digital healthcare platform Balanced wants to help them better manage healthy ageing, says CEO Katie Reed

TrueBinding’s antibody drugs fight Alzheimer’s Disease

Medical Devices & Pharma

Cardinal Health’s clinically integrated pharma supply chain

Medical Devices & Pharma

Healthcare Digital news roundup: digital healthcare & AI

Digital Healthcare